we don't need to wait for very long hopefully, reading in between the lines for half yearly that the results are better than phase 2 trial. There should be atleast 10-15 percent extra improvement in overall results than phase 2. Advanz pharma is very experienced company in making deals in Pharmaceuticals sector. $230 million In upfront and milestone payments plus royalties to DXB between mid teens to twenty percent seems like they are desperate to make deals with DXB, We still have US atleast $2 billion market for FSGS, China and rest of Asia which we have not accounted for. It will follow the trajectory of NEU, Keep your fingers crossed it has the potential to be pharmaceutical unicorn of 2024 and billion dollars company
Interim Analyses of Clinical Trials, page-101
-
- There are more pages in this discussion • 85 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
45.0¢ |
Change
-0.040(8.16%) |
Mkt cap ! $250.7M | |||
| Open | High | Low | Value | Volume |
| 48.5¢ | 48.5¢ | 44.8¢ | $1.098M | 2.375M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 337999 | 45.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 46.0¢ | 17466 | 1 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| DXB (ASX) Chart |